Pet Financial News
New information from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD examine and subcutaneous formulation offered at CTAD
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) accomplice Eisai at the moment offered new information on the investigational...
Pet Financial News
New information from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD research and subcutaneous formulation introduced at CTAD
STOCKHOLM, Oct. 25, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) companion Eisai right this moment introduced new information on the investigational...
Pet Financial News
Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer’s Disease From Additional...
Investigational Subcutaneous Formulation Clears 14% More Plaque Than IV, Pharmacokinetics (AUC) 11% Higher, And Similar ARIA Rates To IV76% Of Patients Showed No Decline...
- Advertisement -
Pet Financial News
New information from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD examine and subcutaneous formulation to be offered at CTAD
STOCKHOLM, Oct. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) accomplice Eisai will current new information from the part 3 Clarity AD...
Pet Financial News
New knowledge from LEQEMBI® (lecanemab-irmb) part 3 Clarity AD research and subcutaneous formulation to be offered at CTAD
STOCKHOLM, Oct. 16, 2023 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) companion Eisai will current new knowledge from the part 3 Clarity AD...
Pet Financial News
Quanterix to Take Part In the 15th Scientific Trials on Alzheimer’s Illness (CTAD) Job Force
Business to supply market viewpoint on making use of emerging blood-based biomarkers tests in Alzheimer's illness scientific trials. BILLERICA, Mass., November 16,...
- Advertisement -
-Advertisement-
Must read
-Advertisement-
